The First, Multicenter, Double-Blind, Randomized, Parallel-Group Study of Certolizumab Pegol in Early Rheumatoid Arthritis Demonstrates Inhibition of Joint Damage Progression.

被引：0
|
作者：
Atsumi, Tatsuya [1 ]
Yamamoto, Kazuhiko [2 ]
Takeuchi, Tsutomu [3 ]
Yamanaka, Hisashi [4 ]
Ishiguro, Naoki [5 ,6 ]
Tanaka, Yoshiya [7 ]
Eguchi, Katsumi [8 ]
Watanabe, Akira [9 ]
Origasa, Hideki [10 ]
Shoji, Toshiharu [11 ]
Togo, Osamu [11 ]
Okada, Toshiyuki [12 ]
van der Heijde, Desiree M. [13 ]
Miyasaka, Nobuyuki [14 ]
Koike, Takao [1 ]
机构：
[1] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan
[2] Univ Tokyo, Tokyo, Japan
[3] Keio Univ, Sch Med, Kitakyushu, Fukuoka, Japan
[4] Tokyo Womens Med Univ, Tokyo, Japan
[5] Nagoya Univ, Grad Sch, Nagoya, Aichi 4648601, Japan
[6] Nagoya Univ, Fac Med, Nagoya, Aichi 4648601, Japan
[7] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka 807, Japan
[8] Sasebo City Gen Hosp, Nagasaki, Japan
[9] Tohoku Univ, Tokyo, Japan
[10] Toyama Univ, Sch Med, Toyama 930, Japan
[11] UCB Pharma, Tokyo, Japan
[12] Astellas Pharma Inc, Tokyo, Japan
[13] Leiden Univ, Med Ctr, Leiden, Netherlands
[14] Tokyo Med & Dent Univ, Tokyo, Japan
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2472
引用
收藏
页码：S1078 / S1079
页数：2
相关论文
共 50 条
  • [1] THE FIRST EARLY RHEUMATOID ARTHRITIS, CERTOLIZUMAB PEGOL, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP STUDY: C-OPERA, IN PATIENTS FULFILLING THE 2010 ACR/EULAR CLASSIFICATION CRITERIA, DEMONSTRATES INHIBITION OF JOINT DAMAGE PROGRESSION
    Atsumi, T.
    Yamamoto, K.
    Takeuchi, T.
    Yamanaka, H.
    Ishiguro, N.
    Tanaka, Y.
    Eguchi, K.
    Watanabe, A.
    Origasa, H.
    Shoji, T.
    Okada, T.
    van der Heijde, D.
    Miyasaka, N.
    Koike, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 484 - 484
  • [2] The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression
    Atsumi, Tatsuya
    Yamamoto, Kazuhiko
    Takeuchi, Tsutomu
    Yamanaka, Hisashi
    Ishiguro, Naoki
    Tanaka, Yoshiya
    Eguchi, Katsumi
    Watanabe, Akira
    Origasa, Hideki
    Yasuda, Shinsuke
    Yamanishi, Yuji
    Kita, Yasuhiko
    Matsubara, Tsukasa
    Iwamoto, Masahiro
    Shoji, Toshiharu
    Okada, Toshiyuki
    van der Heijde, Desiree
    Miyasaka, Nobuyuki
    Koike, Takao
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (01) : 75 - 83
  • [3] Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
    Genovese, Mark C.
    Jarosova, Katerina
    Cieslak, Dorota
    Alper, Jeffrey
    Kivitz, Alan
    Hough, Douglas R.
    Maes, Peter
    Pineda, Lilia
    Chen, Mindy
    Zaidi, Farrukh
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67 (07) : 1703 - 1710
  • [4] NABUMETONE COMPARED WITH NAPROXEN IN THE TREATMENT OF RHEUMATOID-ARTHRITIS - A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP TRIAL IN HOSPITAL OUTPATIENTS
    EMERY, P
    CLARKE, A
    WILLIAMS, P
    KILL, D
    CREE, F
    REDHEAD, R
    POLAND, M
    [J]. ARTHRITIS AND RHEUMATISM, 1992, 35 (09): : S235 - S235
  • [5] FELODIPINE VERSUS MODURETIC - A DOUBLE-BLIND PARALLEL-GROUP MULTICENTER STUDY
    KRONIG, B
    FLYGT, G
    [J]. DRUGS, 1987, 34 : 162 - 169
  • [6] Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis Findings of a Fifty-Two-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
    Keystone, Edward
    van der Heijde, Desiree
    Mason, David, Jr.
    Landewe, Robert
    van Vollenhoven, Ronald
    Combe, Bernard
    Emery, Paul
    Strand, Vibeke
    Mease, Philip
    Desai, Chintu
    Pavelka, Karel
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (11): : 3319 - 3329
  • [7] Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain - Study protocol for a randomized double-blind controlled study
    Schenker, H. M.
    Tascilara, K.
    Konerth, L.
    Sergeeva, M.
    Prade, J.
    Strobelt, S.
    Kleyer, A.
    Simon, D.
    Mendez, L.
    Hagen, M.
    Schoenau, V.
    Hueber, A.
    Roesch, J.
    Doerfler, A.
    Hess, A.
    Schett, G.
    Rech, J.
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2021, 22
  • [8] THE FIRST STUDY OF CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS LED TO SUSTAINED CLINICAL RESPONSE AND INHIBITION OF RADIOGRAPHIC PROGRESSION AT 52 WEEKS: THE C-EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY
    Emery, P.
    Bingham, C. O.
    Burmester, G. -R.
    Bykerk, V. P.
    Furst, D. E.
    Mariette, X.
    van der Heijde, D.
    Tatla, D.
    Arendt, C.
    Mountian, I.
    VanLunen, B.
    Weinblatt, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 712 - 712
  • [9] Wangbi capsule for active rheumatoid arthritis:a multicenter,randomized,double-blind,parallel-controlled study
    吴金联
    [J]. ChinaMedicalAbstracts(InternalMedicine), 2024, 41 (02) - 81
  • [10] One-Year Safety of Sirukumab Monotherapy: Results from a Randomized, Double-Blind, Parallel-Group, Multicenter Study in Japanese Subjects with Moderate to Severe Rheumatoid Arthritis
    Takeuchi, Tsutomu
    Yamanaka, Hisashi
    Harigai, Masayoshi
    Tamamura, Ryo
    Kato, Yuchi
    Ukyo, Yoshifumi
    Nakano, Toshikazu
    Ota, Takayuki
    Hsu, Benjamin
    Tanaka, Yoshiya
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
12345